The negative study result for the drug, called SAGE-324, is a significant setback for Sage’s neurology pipeline, and its effort to develop a successful medicine beyond Zurzuvae, ...

Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill developer.

Biogen and Sage Therapeutics are discontinuing further development of their drug Zurzuvae as a potential treatment for major depressive disorder, a move that follows last year’s FDA rejection of ...

SAGE-324 was one of two Sage drugs licensed by Biogen in 2020 in a $3 billion deal – including more than $1.5 billion upfront – that also gave it rights to zuranolone for psychiatric disorders ...

Biogen and Sage will shut down the ongoing study of SAGE-324. On today's stock market, Sage stock collapsed 20.6% to 10.38. Biogen stock gained a fraction, closing at 226.03.

Sage Therapeutics Inc. plunged after a mid-stage study of its drug to treat essential tremor failed, the second setback for its pipeline in three months. The medicine didn’t significantly reduce ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sage Therapeutics is restructuring yet again ...

Sage has one other approved postpartum depression drug, Zulresso, which works the same way zuranolone does but has to be administered during a 60-hour inpatient IV. Zulresso did $3.3 million in ...

The drug, Zurzuvae (zuranolone), is the first FDA-approved drug to treat postpartum depression, but Sage and its partner Biogen have not yet announced the list price.